B

Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315

Watchlist Manager
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
Watchlist
Price: 5.6 HKD -2.78% Market Closed
Market Cap: 2.2B HKD
Have any thoughts about
Biocytogen Pharmaceuticals Beijing Co Ltd?
Write Note

Gross Margin
Biocytogen Pharmaceuticals Beijing Co Ltd

72%
Current
72%
Average
63.2%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
72%
=
Gross Profit
576.2m
/
Revenue
800.6m

Gross Margin Across Competitors

Country CN
Market Cap 2.2B HKD
Gross Margin
72%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 300.2B USD
Gross Margin
67%
Country US
Market Cap 158.7B USD
Gross Margin
60%
Country US
Market Cap 126.8B USD
Gross Margin
86%
Country US
Market Cap 115B USD
Gross Margin
78%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 137.3B AUD
Gross Margin
52%
Country US
Market Cap 88.3B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 34.1B EUR
Gross Margin
89%

Profitability Report

View the profitability report to see the full profitability analysis for Biocytogen Pharmaceuticals Beijing Co Ltd.

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
72%
=
Gross Profit
576.2m
/
Revenue
800.6m
What is the Gross Margin of Biocytogen Pharmaceuticals Beijing Co Ltd?

Based on Biocytogen Pharmaceuticals Beijing Co Ltd's most recent financial statements, the company has Gross Margin of 72%.